WEC
ZYNE

Winslow Evans & Crocker’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Winslow Evans & Crocker’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-50
Closed -$2K – 1375
2019
Q1 		$2K Sell
50
-900
-95% -$4.38K ﹤0.01% 1291
2018
Q4 		$4K Hold
950
– – ﹤0.01% 982
2018
Q3 		$8K Hold
950
– – ﹤0.01% 864
2018
Q2 		$10K Hold
950
– – ﹤0.01% 820
2018
Q1 		$8.26K Hold
950
– – ﹤0.01% 826
2017
Q4 		$11.9K Buy
950
+900
+1,800% +$10.3K ﹤0.01% 774
2017
Q3 		$418 Hold
50
– – ﹤0.01% 1093
2017
Q2 		$849 Hold
50
– – ﹤0.01% 1218
2017
Q1 		$1.01K Buy
+50
New +$994 ﹤0.01% 1188

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Winslow Evans & Crocker's ZYNE Position: Q2 2019 in Review

Winslow Evans & Crocker sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q2 2019, closing a stake of 50 shares — an estimated $2K sold.

Winslow Evans & Crocker first reported a position in ZYNE in Q1 2017 and held it in 9 quarters. The position peaked at $11.9K in Q4 2017. 76 funds tracked by Wall St. Rank hold ZYNE as of Q2 2019.

  • Winslow Evans & Crocker reported no remaining Zynerba Pharmaceuticals, Inc position as of Q2 2019 after selling out during the quarter.
  • Winslow Evans & Crocker sold 50 Zynerba Pharmaceuticals, Inc shares in Q2 2019, an estimated $2K.
  • Winslow Evans & Crocker first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2017 and held it in 9 quarters.
  • Winslow Evans & Crocker's Zynerba Pharmaceuticals, Inc position peaked at $11.9K in Q4 2017.
  • 76 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q2 2019.

Based on Winslow Evans & Crocker's 13F filing for Q2 2019, filed 19 Jul 2019.